Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brian Yang

Managing Editor

Beijing, China

Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.

Latest From Brian Yang

COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says

CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.

China Vaccines

Chinese Biotech Expects Limited Impact From SVB Aftermath

Favored by venture capital funds, Silicon Valley Bank has served biotech firms conducting transactions in the US. But its collapse is generating a ripple effect on Chinese start-ups already hard hit by a funding crunch.

China Financing

A Closing Door? New China Leadership Takes Reins Amid Growth Anxiety

China's just-concluded National Congress elected new senior government leadership, but shifting top-level policy priorities and a worsening wider operating environment mean observers are worried about continued growth and ongoing pressures on drug pricing.

China Policy

Controversial China Gene Editing Scientist's New Activities Prompt Criticism, Support

Previously jailed gene editing scientist Jiankui He was absent from a recent international genome editing summit, but his renewed activities are generating new concerns five years after the Chinese researcher shocked the world by announcing the birth of gene-edited babies.  

China Gene Therapy

China New Government Policies Taking Shape As Two Sessions Underway

Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.

Policy China

China Business Pessimism Grows Amid COVID Origin Assessment, Congressional Hearing

Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.

Regulation Risk Management
See All
UsernamePublicRestriction

Register